Shanghai.China, June 5, 2020 - ABM Therapeutics, Inc., a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastasis today announced two cancer research posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place from June 22-24. It's the first time for ABM to disclose preclinic data of the clinic phase compound ABM-1310.
Due to the COVID-19 pandemic, AACR, the oldest and largest cancer research organization in the world, has changed the conventional 2020 annual conference into an online format. After AACR Virtual Meeting I on April 27-28, AACR will hold the second portion on June 22-24. ABM Therapeutics will have two posters to present preclinic results of clinic phase compound ABM-1310.
In the session of Novel Antitumor Agents 1
Preclinical development of ABM-1310, a novel BRAF Inhibitor to treat cancer with brain metastasis
In this poster, for the first time, ABM will present the chemical, biology, DMPK and pharmacology properties of ABM-1310, a novel brain-permeable BRAF inhibitor. ABM-1310 is a highly selective and potent BRAF inhibitors as shown in human kinase panel screen and cellular assay screen. It has novel chemical structure with premier solubility, stability, and cell & BBB permeability. Compared to marketed BRAF inhibitor Vemurafenib and Dabrafenib (data not included), in intracranial or intracardiac BRAF V600E mutant melanoma xenograft model or in glioblastoma with BRAF V600E mutant xenograft model, ABM-1310 shown significant improvement in inhibiting tumor growth in brain. GLP toxicity also shown ABM-1310’s premier safety profile.
In the session of Drug Discovery 1
ABM-1310, A novel BRAF Inhibitor, combined with EGFR and MEK inhibitors, inhibits colorectal tumor growth and increases overall survival in vivo
This poster will show that ABM-1310 alone or combo with cetuximab (anti-EGFR antibody) and Binimetinib (MEK inhibitor) had significant anti-tumor growth effects in aBRAF V600E mutant colon cancer HT-29 xenograft model. Compared with marketed BRAF inhibitor Encorafenib (Pfizer/Array Bio), in the HT-29 xenograft, ABM-1310 achieved similar or even better efficacy and had more sustained tumor growth inhibition. This might result from the fact that ABM-1310 was not a P-glycoprotein 1 substrate, which is a common cause of drug-resistance via efflux effect. Western blot results confirmed this difference. ABM-1310 also shown good anti-tumor growth effects in a HT-29 colon orthotopic model, as well as an intracranial xenograft model. Due to its good penetration to the brain, ABM-1310 significantly inhibited tumor growth in the brain and prolonged the median survival time of animals from 38 days (vehicle) to more than 90 days, while the marketed drug Vemurafenib only gave 51 days. ABM-1310 might be a good candidate to treat colorectal cancer with BRAF V600E mutant with or without brain metastasis.
Please find more information about ABM-1310 at AACR website(https://www.aacr.org/meeting/aacr-annual-meeting-2020/aacr-virtual-annual-meeting-i/) from June 22 to 24.
ABM-1310, the first drug candidate of ABM Therapeutics, is a highly water-soluble and cell/brain-permeable BRAF inhibitor for the treatment of cancers with BRAF V600E oncogenic driver and brain metastases. ABM-1310 significantly prolonged median survival time of brain metastases in preclinical models and is expected to be a new generation of BRAF inhibitors for the treatment of various malignant tumors and brain metastases. It was granted clearance of the Investigational New Drug (IND) application to proceed with the first-in-human clinical trial on November 29, 2019. (Clinical trial information: NCT04190628). More information about ABM’s ongoing ABM-1310 trial is available at www.ClinicalTrials.gov and on the company website at www.abmtx.com.
ABM Therapeutics, Inc., founded in 2015, is a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, with a focus on brain cancer and cancer metastasis. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaborations with CROs. ABM’s pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet need of treating cancer and metastases in the brain.
Founded in 1907, the American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. It has over 47,000 members in 127 countries and territories. The mission of AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. The AACR Annual Meeting is one of the largest cancer research conferences in the world, attracting nearly 20,000 professionals from across the globe each year